- Home
- ACGLO vs EXEL Comparison
ACGLO vs EXEL Comparison
Compare ACGLO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACGLO
- EXEL
- Stock Information
- Founded
- ACGLO N/A
- EXEL 1994
- Country
- ACGLO Bermuda
- EXEL United States
- Employees
- ACGLO 5800
- EXEL N/A
- Industry
- ACGLO Property-Casualty Insurers
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACGLO Finance
- EXEL Health Care
- Exchange
- ACGLO Nasdaq
- EXEL Nasdaq
- Market Cap
- ACGLO N/A
- EXEL 9.8B
- IPO Year
- ACGLO N/A
- EXEL 2000
- Fundamental
- Price
- ACGLO $20.76
- EXEL $38.47
- Analyst Decision
- ACGLO
- EXEL Buy
- Analyst Count
- ACGLO 0
- EXEL 18
- Target Price
- ACGLO N/A
- EXEL $37.59
- AVG Volume (30 Days)
- ACGLO N/A
- EXEL 2.4M
- Earning Date
- ACGLO N/A
- EXEL 05-02-2025
- Dividend Yield
- ACGLO N/A
- EXEL N/A
- EPS Growth
- ACGLO N/A
- EXEL 170.77
- EPS
- ACGLO N/A
- EXEL 1.76
- Revenue
- ACGLO N/A
- EXEL $2,168,701,000.00
- Revenue This Year
- ACGLO N/A
- EXEL $5.82
- Revenue Next Year
- ACGLO N/A
- EXEL $10.81
- P/E Ratio
- ACGLO N/A
- EXEL $21.27
- Revenue Growth
- ACGLO N/A
- EXEL 18.50
- 52 Week Low
- ACGLO N/A
- EXEL $20.14
- 52 Week High
- ACGLO N/A
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- ACGLO 54.50
- EXEL 57.87
- Support Level
- ACGLO $19.99
- EXEL $35.34
- Resistance Level
- ACGLO $20.32
- EXEL $37.67
- Average True Range (ATR)
- ACGLO 0.31
- EXEL 1.32
- MACD
- ACGLO 0.09
- EXEL 0.22
- Stochastic Oscillator
- ACGLO 92.31
- EXEL 95.46
About ACGLO Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.